i tuoi badge Intervallo 52 sett. $123–$186 34% of range Rating Analisti BUY 36 analysts Prezzo Obiettivo $208 +44% upside P/E 21.1 ROE 22.1% Margine di Profitto Netto 20.9%

NBIX Snapshot del titolo Prezzo, capitalizzazione di mercato, P/E, EPS, ROE, debito/capitale proprio, intervallo 52 settimane

03
Prezzo $144.21
Capitalizzazione di Mercato (MRQ) $14.65B
P/E (TTM) 21.1
EPS (TTM) $6.83
Ricavi (TTM) $3.37B
ROE (TTM) 22.1%
Intervallo 52 sett. $123–$186

NBIX Grafico del prezzo delle azioni OHLCV giornaliero con indicatori tecnici — panoramica, zoom e personalizza la tua visualizzazione

04
intervallo
barre

La granularità delle barre si adatta al periodo selezionato — passa il mouse sul grafico per vedere apertura/massimo/minimo/chiusura di una barra.

Informazioni su Neurocrine Biosciences, Inc. - Common Stock Panoramica della società da Wikipedia

05 · wikidata

Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).

The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids.

History

Neurocrine was founded in San Diego, California, in 1992. The company's academic founders were Wylie Vale of the Salk Institute for Biological Studies, and Lawrence Steinman of Stanford University. The company was backed and organized by Larry Bock of Avalon Ventures among others.

In 1995, the company collaborated with Belgium-based Janssen Pharmaceutica N.V. to develop treatments for psychiatric disorders utilizing corticotropin releasing factor (CRF) antagonists, a class of compounds to treat psychiatric, neurological and gastrointestinal diseases including anxiety, depression and irritable bowel syndrome. The company underwent an IPO in May 1996, listing on the NASDAQ exchange under the symbol NBIX and raising $34.2 million.

In October 1996, Eli Lilly and Company agreed to pay Neurocrine $74 million over five years to develop drugs for obesity and Alzheimer's disease based on its research of CRF-binding protein-ligand inhibitors.

In July 2001, Neurocrine and GlaxoSmithKline entered into a worldwide research, development and commercialization agreement, including a collaborative research program for up to five years to identify and develop CRF-R antagonist compounds. The collaboration also included worldwide development and commercialization of NBI-34041 as well as potential backup candidates resulting from the research program. Neurocrine received upfront fees and early milestone payments totaling $25.5 million.

In December 2002, Neurocrine reached an agreement with Pfizer for the rights to its experimental insomnia drug, indiplon. The deal paid Neurocrine $100 million initially with a possible $300 million more if the drug met regulatory and sales goals. In May 2006, the FDA issued a non-approvable letter for a modified-release 15 mg formulation of indiplon and an approvable letter with stipulations for 5 mg and 10 mg immediate-release formulations. As a result, Pfizer terminated its agreement with Neurocrine. Following a resubmission of the 5 mg and 10 mg formulations in December 2007, Neurocrine's new drug application was deemed 'approvable' but the FDA requested additional studies. The company discontinued development of the drug in the United States. In 2007, Neurocrine partnered with Dainippon Sumitomo Pharma to develop and commercialize indiplon in Japan. The deal paid Neurocrine $20 million up front with the ability to receive milestone payments and royalties based on the commercialization of indiplon in Japan.

Kevin Gorman replaced Gary Lyons as CEO of the company in January 2008. Lyons was CEO and president of the company since its founding and maintained a role on the company's board of directors.

On June 16, 2010, Neurocrine agreed to a deal with AbbVie Inc. (previously Abbott Laboratories) worth up to $575 million with Neurocrine granting AbbVie the worldwide rights to develop and commercialize elagolix, an oral gonadotropin-releasing hormone (GnRH) antagonist to treat endometriosis and uterine fibroids. The deal paid Neurocrine $75 million up front.

In April 2017, the FDA approved valbenazine for the treatment of TD. At the time of approval, it was the first and only drug approved for adults with TD. Neurocrine is also studying valbenazine in clinical trials for the treatment of Tourette Syndrome. In October 2017, Neurocrine announced that it had been granted orphan drug designation status from the FDA for valbenazine for the treatment of pediatric patients with Tourette syndrome.

In February 2017, Neurocrine announced an exclusive licensing agreement for the development and commercialization of the Parkinson's disease drug, opicapone, in North America with the Portugal-based pharmaceutical company Bial. As part of the agreement, Neurocrine provided an upfront payment of $30 million and agreed to fund development activities for FDA approval in the United States. Bial is eligible to receive additional milestone payments of up to $115 million and a percentage of net sales.

In September 2017, AbbVie submitted a NDA to the FDA for elagolix for the management of endometriosis and associated pain. The submission was supported by two similar Phase 3 clinical studies involving 1,700 women. In October 2017, AbbVie and Neurocrine announced that the FDA granted priority review for the elagolix NDA. A final regulatory decision on the drug will come during the third quarter of 2018. The companies are also developing elagolix for the treatment of uterine fibroids which is in Phase III development.

In 2021,Nexera Pharmain Japan licensed out its investigational schizophrenia drug, NBI-1117568, to Neurocrine Biosciences for development.

In August 2024, Neurocrine announced the results of a Phase II clinical trial of NBI-1117568 . The drug demonstrated a 7.5-point improvement in the Positive and Negative Syndrome Scale (PANSS), which was lower than the 8.4-point improvement seen with KarXT (developed by Karuna Therapeutics) and the 12.7-point improvement seen with Emraclidine (developed by Cerevel Therapeutics), both of which were also in clinical trials at the time. Additionally, the study found no dose-dependent response to NBI-1117568. As a result, Neurocrine's stock price fell 19% the following day as investors were disappointed by the results.

Product pipeline

Elagolix – gonadotropin-releasing hormone receptor antagonist undergoing FDA review for the treatment of endometriosis and in clinical trials for uterine fibroids

Opicapone – A once daily catechol-O-methyl transferase inhibitor in trials for Parkinson's disease

NBI-74788 – Corticotropin-releasing factor (CRF) receptor antagonist

NBI-1117568 - A drug that stimulates muscarinic receptors and is used to treat schizophrenia.

Fonte: Wikipedia (Inglese), CC BY-SA 4.0 · Vedi su Wikipedia ↗

Wikidata ↗

settoreHealthcare industriaBiotechnology dipendenti2.500 paeseUS

Performance decennale Andamento di ricavi, utile netto, margini e EPS

06
Ricavi$2.86B
2016-12-31 → 2025-12-31
EPS$4.67
2016-12-31 → 2025-12-31
Flusso di cassa libero$749M
2016-12-31 → 2025-12-31
Margine netto20.9%
2016-12-31 → 2025-12-31
Valutazione e Rapporti 07–12

Valutazione Rapporti P/E, P/S, P/B, EV/EBITDA — il titolo è costoso o economico?

Metrica Tendenza 5 anni NBIX media 5 anni Mediana dei peer Verdetto
P/E (TTM) 21.1media 5 anni ≈58.9 ≈58.9 19.4 Sopravvalutato
P/S (TTM) 4.3media 5 anni ≈6.5 ≈6.5 7.3 Sottovalutato
P/B (MRQ) 4.0media 5 anni ≈5.6 ≈5.6 14.5 Sottovalutato
Prezzo / FCF (TTM) 16.8media 5 anni ≈29.9 ≈29.9 · ·
Prezzo / Flusso di cassa (TTM) 16.3media 5 anni ≈28.0 ≈28.0 13.6 Sopravvalutato
Prezzo / Valore contabile tangibile (MRQ) 10.0media 5 anni ≈5.7 ≈5.7 · ·
PEG Ratio ≈9.0 · · ·

La mediana dei peer viene calcolata su base standardizzata per metrica e potrebbe non corrispondere sempre alla base TTM/MRQ mostrata per questo titolo.

valore · ≈ media 5 anni · mediana del settore · giudizio rispetto alla mediana

Cronologia utili EPS effettivo vs stima, surprise %, tasso di superamento, data prossimi utili

14
Sorpresa media 11.3%
Prossimo report Ott 26, 2026
PeriodoRapportoEPS ActualEPS StimatoSorpresa
30 Giugno 2026 Lug 28, 2026 $1.39 $1.37 1.5%
31 Marzo 2026 $1.91 $1.20 59.5%
31 Dicembre 2025 $1.91 $1.20 59.5%
30 Settembre 2025 $2.04 $1.62 26.1%
30 Giugno 2025 $1.06 $0.99 7.0%
31 Marzo 2025 $0.08 $0.56 -85.6%

Fondamentali Completi Tutte le metriche per anno — conto economico, stato patrimoniale, rendiconto finanziario

15
Conto Economico 17
Metrica Tendenza 202520242023202220212020201920182017201620152014
Revenue $2.86B$2.36B$1.89B$1.49B$1.13B$1.05B$788M$451M$162M$15M$20M$0
Cost of Revenue $52M$34M$40M$23M$14M$10M·$5M$1M$0$0·
R&D Expense ·······$161M$122M$94M$81M$46M
SG&A Expense $1.16B$1.01B$888M$753M$583M$433M$354M$249M$170M$68M$32M$18M
Operating Expenses $2.24B$1.78B$1.64B$1.24B$1.03B$883M$716M$414M$293M$162M$114M$64M
Operating Income $619M$570M$251M$249M$102M$163M$72M$37M$-131M$-147M$-94M$-64M
Interest Expense ··$5M$7M$26M$33M$32M$30M$20M$0$0·
Interest Income ·········$3M$2M$629.0K
Other Non-op $86M$-84M$81M$-35M$-1M$-56M$-26M$-15M$-11M$6M$20.0K$18.0K
Pretax Income $705M$486M$332M$214M$101M$107M$46M$22M$-143M$-141M··
Income Tax $227M$145M$82M$59M$12M$-301M$10M$700.0K$0$0$0$0
Net Income $479M$341M$250M$154M$90M$407M$37M$21M$-143M$-141M$-89M$-61M
EPS (Basic) $4.81$3.40$2.56$1.61$0.95$4.38$0.40$0.23$-1.62$-1.63$-1.05$-0.81
EPS (Diluted) $4.67$3.29$2.47$1.56$0.92$4.16$0.39$0.22$-1.62$-1.63$-1.05$-0.81
Shares (Basic) 99,500,000100,400,00097,700,00095,800,00094,600,00093,100,00091,600,00090,200,00088,089,00086,713,00084,496,00074,577,000
Shares (Diluted) 102,500,000103,700,000101,000,00098,900,00097,900,00097,800,00095,700,00095,400,00088,089,00086,713,00084,496,00074,577,000
EBITDA $619M$570M$251M$249M$102M$163M$72M$37M$-131M$-147M·$-64M
Stato Patrimoniale 28
Metrica Tendenza 202520242023202220212020201920182017201620152014
Cash & Equivalents $713M$233M$251M$263M$341M$187M$112M$142M$255M$83M$74M$31M
Short-term Investments ····$370M$614M$558M$509M$261M$224M$305M$163M
Receivables $687M$479M$439M$350M$186M$157M$127M$57M$31M$0··
Inventory $69M$57M$38M$35M$30M$28M$17M$11M$1M$0··
Prepaid Expense $171M$48M··········
Other Current Assets $116M$64M$98M$79M$46M$30M$17M$19M$7M$3M$5M$4M
Current Assets $2.52B$1.72B$1.61B$1.45B$973M$1.02B$831M$738M$555M$310M$384M$198M
PP&E (Net) $90M$83M$71M$59M$59M$45M$42M$34M$11M$6M$3M$3M
PP&E (Gross) $208M$189M$154M$125M$110M$86M$76M$62M$38M$32M$30M$31M
Accum. Depreciation $118M$106M$83M$66M$52M$42M$34M$28M$28M$26M$27M$29M
Goodwill $6M$6M$6M$5M$0·······
Intangibles $5M$36M$36M$37M$0·······
Other Non-current Assets $49M$52M$50M$25M$4M$6M$0·····
Total Assets $4.63B$3.72B$3.25B$2.37B$2.07B$1.73B$1.31B$993M$818M$365M$475M$243M
Accounts Payable $674M$462M$449M$348M$226M$169M$141M$86M$6M$5M$3M$246.0K
Accrued Liabilities ·········$21M$19M$12M
Current Liabilities $743M$508M$655M$538M$246M$186M$565M$88M$54M$30M$26M$16M
Capital Leases $415M$455M$258M$94M$105M$94M$87M$0····
Deferred Tax $0···········
Other Non-current Liabilities $220M$166M$106M$30M$12M$10M$17M$36M$0$113.0K$221.0K$260.0K
Total Liabilities $1.38B$1.13B$1.02B$661M$698M$608M$669M$512M$445M$50M$50M$34M
Common Stock $100.0K$100.0K$100.0K$100.0K$100.0K$100.0K$100.0K$91.0K$89.0K$87.0K$86.0K$76.0K
Paid-in Capital ···········$1.04B
Retained Earnings $448M$29M$-157M$-407M$-636M$-725M$-1.13B$-1.18B$-1.20B$-1.06B$-915M$-826M
AOCI $13M$6M$7M$-8M$-2M$2M$1M$-2M$-2M$-318.0K$-977.0K$-277.0K
Stockholders' Equity $3.25B$2.59B$2.23B$1.71B$1.37B$1.13B$637M$481M$372M$315M$424M$209M
Liabilities + Equity $4.63B$3.72B$3.25B$2.37B$2.07B$1.73B$1.31B$993M$818M$365M$475M$243M
Shares Outstanding 100,100,00099,400,00098,700,00096,500,00094,900,00093,500,00092,300,00090,797,00088,793,90386,883,30086,262,59476,465,942
Flusso di cassa 15
Metrica Tendenza 202520242023202220212020201920182017201620152014
D&A ·······$4M$2M$1M$1M$827.0K
Stock-based Comp $218M$196M$194M$173M$134M$100M$75M$58M$43M$28M$28M$10M
Deferred Tax $164M$-123M$-61M$22M$6M$-311M$0$0····
Amort. of Intangibles $4M$4M$4M$500.0K$0$0······
Operating Cash Flow $783M$595M$390M$339M$256M$228M$147M$101M$-94M$-106M$-38M$-47M
CapEx $34M$38M$28M$16M$23M$11M$15M$25M$7M$4M$2M$2M
Investing Cash Flow $-264M$-127M$-467M$-177M$-130M$4M$-211M$-243M$-251M$113M··
Stock Issued $129M$122M$65M$45M$28M$29M$32M$30M$14M$2M$277M$139M
Stock Repurchased $168M$300M$0$0········
Net Stock Activity $-38M$-178M$65M$45M$28M$29M$27M$30M$14M$2M·$139M
Financing Cash Flow $-38M$-487M$65M$-234M$27M$-158M$32M$30M$517M$2M··
Net Change in Cash $480M$-18M$-12M$-73M$154M$75M$-32M$-112M$171M$9M$43M$-14M
Taxes Paid $81M···········
Free Cash Flow $749M$557M$362M$323M$233M$218M$137M$77M$-101M$-110M·$-49M
Levered FCF ··$358M$318M$210M$92M$112M$47M····
Redditività 7
Metrica Tendenza 202520242023202220212020201920182017201620152014
Operating Margin 21.6%24.2%13.3%16.7%9.0%15.6%9.2%8.2%-81.3%-982.5%··
Net Margin 16.7%14.5%13.2%10.4%7.9%38.9%4.7%4.7%-88.2%-940.6%··
Pretax Margin 24.7%20.6%17.6%14.4%8.9%10.2%5.9%4.8%····
EBITDA Margin 21.6%24.2%13.3%16.7%9.0%15.6%9.2%8.2%-81.3%-982.5%··
ROA 11.5%9.8%8.9%7.0%4.7%26.8%3.2%2.3%-24.1%-33.6%·-30.4%
ROE 16.1%12.9%11.8%9.5%6.6%42.2%6.1%4.5%-41.5%-38.2%·-36.8%
ROIC 12.9%15.5%8.5%10.5%6.6%55.2%9.0%7.4%····
Liquidità e Solvibilità 3
Metrica Tendenza 202520242023202220212020201920182017201620152014
Current Ratio 3.43.42.52.74.05.41.58.410.210.2·12.7
Quick Ratio 1.91.41.11.13.65.11.42.210.110.1·12.4
Interest Coverage ··54.535.14.05.02.31.2-6.7···
Efficienza 3
Metrica Tendenza 202520242023202220212020201920182017201620152014
Asset Turnover 0.70.70.70.70.60.70.70.50.30.0·0.0
Inventory Turnover 0.80.71.10.7···0.8····
Receivables Turnover 4.95.14.85.66.67.48.610.310.4···
Per Azione 5
Metrica Tendenza 202520242023202220212020201920182017201620152014
Book Value / Share $32.50$26.05$22.61$17.70$14.48$12.04$6.90$5.29$4.19$3.62·$2.73
Revenue / Share $27.91$22.71$18.68$15.05$11.58$10.69$8.23$4.73$1.83$0.17·$0.00
Cash Flow / Share $7.64$5.74$3.86$3.43$2.62$2.34$1.59$1.06$-1.07$-1.22·$-0.63
Cash / Share $7.12$2.34$2.54$2.72$3.59$2.00$1.22$1.56$2.87$0.96·$0.41
EPS (TTM) $4.67$3.29$2.47$1.56$0.92$4.16$0.39$0.22$-1.62$-1.63$-1.05$-0.81
Tassi di Crescita 9
Metrica Tendenza 202520242023202220212020201920182017201620152014
Revenue YoY 21.4%24.8%26.8%31.3%8.4%·······
Revenue CAGR 3Y 24.3%27.6%21.7%·········
Revenue CAGR 5Y 22.3%···········
EPS YoY 41.9%33.2%58.3%69.6%-77.9%·······
EPS CAGR 3Y 44.1%52.9%-16.0%·········
EPS CAGR 5Y 2.3%···········
Net Income YoY 40.2%36.7%61.6%72.4%-78.0%·······
Net Income CAGR 3Y 45.8%56.2%-15.0%·········
Net Income CAGR 5Y 3.3%···········
Valutazione (TTM) 10
Metrica Tendenza 202520242023202220212020201920182017201620152014
Revenue TTM $2.86B$2.36B$1.89B$1.49B$1.13B$1.05B$788M$451M$162M$15M$20M$0
Net Income TTM $479M$341M$250M$154M$90M$407M$37M$21M$-143M$-141M$-89M$-61M
Market Cap $14.20B$13.57B$13.00B$11.53B$8.08B$8.96B$9.92B$6.48B$6.89B$3.36B·$1.71B
P/E 30.441.553.376.692.623.0275.6324.6-47.9-23.7-53.9-27.6
P/S 5.05.86.97.77.18.612.614.442.6224.2··
P/B 4.45.25.86.75.98.015.613.518.510.7·8.2
P / Tangible Book 4.45.35.96.95.98.0······
P / Cash Flow 18.122.833.434.031.539.265.264.0-73.0-31.7·-36.2
P / FCF 19.024.436.035.734.741.272.284.7-68.0-30.5·-35.0
Earnings Yield 3.3%2.4%1.9%1.3%1.1%4.3%0.36%0.31%-2.1%-4.2%-1.9%-3.6%

Periodo più recente a sinistra · valori nulli mostrati come ·

Bilanci Conto economico, stato patrimoniale, flusso di cassa — annuale, ultimi 5 anni

16
Metrica 2025-12-312024-12-312023-12-312022-12-312021-12-31
Ricavi $2.86B $2.36B $1.89B $1.49B $1.13B
Margine Operativo % 21.6% 24.2% 13.3% 16.7% 9.0%
Utile netto $479M $341M $250M $154M $90M
EPS Diluito $4.67 $3.29 $2.47 $1.56 $0.92

Proprietari istituzionali (13F) 825 filer · $18.1B totale · Aggiornato al 30 Settembre 2026

17

Istituzioni che segnalano il possesso di questo titolo nel loro Modulo SEC 13F trimestrale. Solo posizioni lunghe; un singolo depositante può apparire due volte per diverse gambe di opzioni. Grandi posizioni put/call contrapposte riflettono tipicamente market-making o inventario coperto, non convinzione direzionale.

Detentori 825
Valore detenuto $18.1B
Nuove posizioni 148
Posizioni chiuse 62
Attività istituzionale — Q2 2026 vs trimestre precedente
Nuove posizioni Posizioni chiuse Aumentato Diminuito Variazione netta delle azioni
148 (+50 vs trimestre precedente) 62 (-36 vs trimestre precedente) 317 (+16 vs trimestre precedente) 226 (+12 vs trimestre precedente) +587K

Confrontato con Q1 2026. Le dichiarazioni SEC Form 13F sono dovute entro 45 giorni dalla fine del trimestre più un breve margine per i dichiaranti in ritardo — i trimestri ancora all'interno di questa finestra vengono saltati a favore della coppia più recente completamente riportata.

Istituzione Valore Azioni % di 13F tracciati Tipo
BlackRock, Inc. $2.310.885.707 13.711.607 12,75% Azioni
VANGUARD GROUP INC $1.375.793.692 9.700.301 7,59% Azioni
JPMORGAN CHASE & CO $1.088.569.109 6.398.674 6,01% Azioni
Dodge & Cox $941.218.594 5.584.707 5,19% Azioni
VANGUARD PORTFOLIO MANAGEMENT LLC $838.307.078 4.974.083 4,63% Azioni
VANGUARD CAPITAL MANAGEMENT LLC $766.048.708 4.545.339 4,23% Azioni
STATE STREET CORP $739.126.759 4.385.598 4,08% Azioni
AQR CAPITAL MANAGEMENT LLC $643.472.716 3.818.037 3,55% Azioni
RENAISSANCE TECHNOLOGIES LLC $393.680.402 2.335.897 2,17% Azioni
GEODE CAPITAL MANAGEMENT, LLC $359.607.676 2.138.777 1,98% Azioni
TWO SIGMA INVESTMENTS, LP $349.922.479 2.076.260 1,93% Azioni
Vestal Point Capital, LP $316.845.800 1.880.000 1,75% Azioni
BNP PARIBAS ASSET MANAGEMENT Holding S.A. $251.858.951 1.494.259 1,39% Azioni
MORGAN STANLEY $222.231.858 1.318.607 1,23% Azioni
RTW INVESTMENTS, LP $213.689.740 1.267.925 1,18% Azioni
NORTHERN TRUST CORP $212.306.405 1.259.717 1,17% Azioni
Invesco Ltd. $181.565.621 1.077.317 1,00% Azioni
CHARLES SCHWAB INVESTMENT MANAGEMENT INC $164.200.136 974.279 0,91% Azioni
NORGES BANK $164.132.866 973.880 0,91% Azioni
FIRST TRUST ADVISORS LP $155.578.851 923.125 0,86% Azioni
DIMENSIONAL FUND ADVISORS LP $123.525.529 732.877 0,68% Azioni
JACOBS LEVY EQUITY MANAGEMENT, INC $122.375.286 726.112 0,68% Azioni
TWO SIGMA ADVISERS, LP $119.504.823 842.592 0,66% Azioni
Bank of New York Mellon Corp $117.826.993 699.125 0,65% Azioni
Swedbank AB $109.730.107 651.082 0,61% Azioni
VANGUARD FIDUCIARY TRUST CO $109.170.737 647.763 0,60% Azioni
IEQ CAPITAL, LLC $107.913.614 640.304 0,60% Azioni
GOLDMAN SACHS GROUP INC $106.495.877 631.892 0,59% Azioni
BANK OF AMERICA CORP /DE/ $104.382.489 619.352 0,58% Azioni
VICTORY CAPITAL MANAGEMENT INC $104.238.729 618.499 0,58% Azioni
Man Group plc $101.292.738 601.019 0,56% Azioni
ROYAL BANK OF CANADA $98.337.000 583.476 0,54% Azioni
RAYMOND JAMES FINANCIAL INC $97.778.953 580.170 0,54% Azioni
FRANKLIN RESOURCES INC $93.211.316 553.068 0,51% Azioni
UBS Group AG $92.009.492 545.937 0,51% Azioni
Caisse de depot et placement du Quebec $91.002.327 539.961 0,50% Azioni
ARMISTICE CAPITAL, LLC $90.307.457 535.838 0,50% Azioni
AMERIPRISE FINANCIAL INC $84.660.571 502.267 0,47% Azioni
PRIMECAP MANAGEMENT CO/CA/ $82.807.988 491.340 0,46% Azioni
Hood River Capital Management LLC $79.082.184 469.233 0,44% Azioni
Nuveen, LLC $77.408.341 459.301 0,43% Azioni
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC $75.318.261 571.719 0,42% Azioni
Pictet Asset Management Holding SA $72.751.030 430.635 0,40% Azioni
Rockefeller Capital Management L.P. $62.955.982 373.548 0,35% Azioni
Fiera Capital Corp $62.895.914 373.192 0,35% Azioni
Gotham Asset Management, LLC $62.622.213 371.568 0,35% Azioni
JANUS HENDERSON GROUP PLC $61.515.240 466.977 0,34% Azioni
ALLIANCEBERNSTEIN L.P. $60.767.710 461.270 0,34% Azioni
Vinva Investment Management Ltd $58.838.530 346.109 0,32% Azioni
AustralianSuper Pty Ltd $58.817.535 348.993 0,32% Azioni

Mostra tutti i 825 proprietari istituzionali →

Attivisti e proprietari del 5%+ 1 partecipazione

18

Investitori che hanno depositato SEC Schedule 13D — proprietà effettiva superiore al 5% con l'intento di influenzare l'emittente (partecipazioni attiviste, campagne per il consiglio di amministrazione, M&A). Ogni riga mostra lo stato più recente noto della posizione di quel depositante.

Depositante Depositato Partecipazione Stato Scopo Deposito
Neurocrine Biosciences, Inc. ×3 depositi 24 Febbraio 2023 · Deposito iniziale · SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Insider aziendali 41 insider · 22 dirigenti · 15 direttori

19
Insider Ruolo Ultima attività Azioni possedute Acquisti 12m Vendite 12m Netto 12m
Kyle Gano Chief Executive Officer 11 Settembre 2026 F 154.728 0 3 $-4.872.890
Matt Abernethy Chief Financial Officer 14 Settembre 2026 S 42.808 0 1 $-363.289
Timothy Coughlin Chief Financial Officer 06 Febbraio 2017 S 137.961 0 0 $0
David-Alexandre C Gros President & COO 06 Febbraio 2017 A · 0 0 $0
David W. Boyer Chief Corp. Affairs Officer 14 Settembre 2026 S 8.722 0 2 $-739.070
Ingrid Delaet Chief Regulatory Officer 11 Settembre 2026 F 18.289 0 5 $-3.747.962
Jude Onyia Chief Scientific Officer 11 Settembre 2026 F 22.647 0 2 $-3.473.580
Sanjay Chandru Keswani Chief Medical Officer 11 Settembre 2026 F 3.281 0 0 $0
Julie Cooke Chief Human Resources Officer 11 Settembre 2026 F 24.025 0 5 $-5.770.377
Eric Benevich Chief Commercial Officer 11 Settembre 2026 F 67.297 0 2 $-1.238.918
Darin Lippoldt Chief Legal Officer 11 Settembre 2026 F 56.793 0 5 $-4.196.071
Eiry Roberts Chief Medical Officer 13 Febbraio 2025 M 35.640 0 0 $0
Malcolm Lloyd-Smith Chief Integration Officer 08 Febbraio 2023 S 42.337 0 0 $0
Dimitri E. Grigoriadis Chief Research Officer 31 Gennaio 2022 A 82.273 0 0 $0
Haig P. Bozigian Chief Development Officer 08 Febbraio 2021 A 157.651 0 0 $0
Christopher Flint Obrien Former Chief Medical Officer 05 Febbraio 2018 A 55.946 0 0 $0
VALEUR JENSEN MARGARET E EVP and General Counsel 31 Agosto 2011 A 118.256 0 0 $0
Richard J Ranieri Sr. VP, Human Resources 27 Febbraio 2008 A 9.667 0 0 $0
Wendall Wierenga EVP, Research & Development 19 Gennaio 2006 A 5.023 0 0 $0
Henry Pan Executive VP and CMO 03 Giugno 2005 A 11.216 0 0 $0
Robert J Little SVP, Commercial Operations 18 Febbraio 2005 A · 0 0 $0
SAUNDERS JOHN Vice President Research (Chem) 18 Dicembre 2003 S 7.966 0 0 $0
Kevin Charles Gorman Direttore 11 Settembre 2026 F 517.797 0 1 $-37.824.431
SHERWIN STEPHEN A Direttore 02 Settembre 2026 G 14.860 0 5 $-4.132.990
Leslie V Norwalk Direttore 29 Luglio 2026 M 2.430 0 5 $-1.973.882
Johanna Mercier Direttore 27 Maggio 2026 A 6.853 0 0 $0
William H Rastetter Direttore 27 Maggio 2026 A 43.678 0 1 $-2.732.760
Christine A Poon Direttore 27 Maggio 2026 A 4.753 0 0 $0
POPS RICHARD F Direttore 27 Maggio 2026 A 37.798 0 1 $-2.364.750
LYONS GARY A Direttore 27 Maggio 2026 A 122.141 0 1 $-2.289.150
MORROW GEORGE J Direttore 27 Maggio 2026 A 10.386 0 1 $-2.150.550
Alfred Sandrock Direttore 22 Maggio 2019 A · 0 0 $0
Corinne H Nevinny Direttore 24 Maggio 2018 A 43.283 0 0 $0
Thomas W Mitchell Direttore 28 Maggio 2015 A 1.000 0 0 $0
VALE WYLIE W Direttore 25 Maggio 2011 A 231.372 0 0 $0
Adrian Adams Direttore 30 Giugno 2006 A · 0 0 $0
Shalini Sharp · 27 Maggio 2026 A 4.088 0 0 $0
MOLLICA JOSEPH A · 22 Maggio 2017 A 56.042 0 0 $0
HAWRAN PAUL W · 18 Settembre 2006 J 132.000 0 0 $0
Lawrence Steinman · 02 Marzo 2005 S 15.500 0 0 $0
CONLON PAUL J · 16 Dicembre 2003 S 57.335 0 0 $0

Insider dai depositi SEC Modulo 3/4/5; netto = solo acquisti/vendite di mercato

Proprietà ETF Posseduti da 104 ETF

20

Il peso riflette solo le partecipazioni azionarie dirette (N-PORT); fondi a leva o basati su derivati possono detenere ulteriore esposizione swap non mostrata.

Fondo Peso Unità Aggiornato al Fonte
IBRN · iShares Trust 3,75% 1.793 SH 11 Settembre 2026 Giornaliero
PBE · Invesco Exchange-Traded Fund Trust 2,60% 76.511 SH 02 Ottobre 2026 Giornaliero
MCOW · Pacer Funds Trust 2,57% 164 NS 31 Luglio 2026 N-PORT
BUL · Pacer Funds Trust 2,15% 16.896 NS 31 Luglio 2026 N-PORT
CVSM · Elevation Series Trust 2,04% 11.525 NS 31 Luglio 2026 N-PORT
JMID · Janus Detroit Street Trust 1,93% 2.742 NS 31 Luglio 2026 N-PORT
POWA · Invesco Exchange-Traded Self-Indexe… 1,92% 22.570 SH 02 Ottobre 2026 Giornaliero
FGSI · First Trust Exchange-Traded Fund IV 1,90% 236 NS 31 Luglio 2026 N-PORT
ABOT · Abacus FCF ETF Trust 1,90% 460 NS 31 Luglio 2026 N-PORT
XMHQ · Invesco Exchange-Traded Fund Trust 1,74% 667.222 SH 02 Ottobre 2026 Giornaliero
FXH · First Trust Exchange-Traded AlphaDE… 1,67% 105.135 NS 31 Luglio 2026 N-PORT
GRPM · Invesco Exchange-Traded Fund Trust 1,61% 56.862 SH 02 Ottobre 2026 Giornaliero
BBP · ETFis Series Trust I 1,44% 8.494 NS 31 Luglio 2026 N-PORT
CSMD · Professionally Managed Portfolios 1,18% 32.094 NS 31 Luglio 2026 N-PORT
IBB · iShares Trust 1,14% 755.021 SH 11 Settembre 2026 Giornaliero
AGRW · ALLSPRING EXCHANGE-TRADED FUNDS TRU… 1,11% 7.516 NS 31 Luglio 2026 N-PORT
JSMD · Janus Detroit Street Trust 1,05% 66.455 NS 31 Luglio 2026 N-PORT
RFG · Invesco Exchange-Traded Fund Trust 1,04% 24.859 SH 02 Ottobre 2026 Giornaliero
IBBQ · Invesco Exchange-Traded Fund Trust … 0,96% 7.190 SH 02 Ottobre 2026 Giornaliero
IVOG · VANGUARD ADMIRAL FUNDS 0,89% 99.214 SH 19 Agosto 2026 Giornaliero
COWG · Pacer Funds Trust 0,78% 103.520 NS 31 Luglio 2026 N-PORT
JDOC · J.P. Morgan Exchange-Traded Fund Tr… 0,73% 399 NS 31 Luglio 2026 N-PORT
LSEQ · Harbor ETF Trust 0,72% 661 NS 31 Luglio 2026 N-PORT
QQQJ · Invesco Exchange-Traded Fund Trust … 0,72% 59.939 SH 02 Ottobre 2026 Giornaliero
LABU · Direxion Shares ETF Trust 0,71% 20.978 NS 31 Luglio 2026 N-PORT
IQSM · New York Life Investments ETF Trust 0,63% 12.528 NS 31 Luglio 2026 N-PORT
FNY · First Trust Exchange-Traded AlphaDE… 0,63% 21.784 NS 31 Luglio 2026 N-PORT
QLV · FlexShares Trust 0,56% 5.460 NS 31 Luglio 2026 N-PORT
ISCG · iShares Trust 0,52% 31.868 SH 11 Settembre 2026 Giornaliero
PTMC · Pacer Funds Trust 0,47% 11.072 NS 31 Luglio 2026 N-PORT
USMV · iShares Trust 0,46% 697.795 SH 11 Settembre 2026 Giornaliero
VBK · VANGUARD INDEX FUNDS 0,46% 1.331.820 SH 19 Agosto 2026 Giornaliero
IVOO · VANGUARD ADMIRAL FUNDS 0,46% 162.408 SH 19 Agosto 2026 Giornaliero
QVMM · Invesco Exchange-Traded Fund Trust … 0,45% 13.252 SH 02 Ottobre 2026 Giornaliero
SMDX · Tidal Trust III 0,43% 3.374 NS 31 Luglio 2026 N-PORT
BKMC · BNY Mellon ETF Trust 0,42% 16.429 NS 31 Luglio 2026 N-PORT
IWP · iShares Trust 0,39% 480.949 SH 11 Settembre 2026 Giornaliero
SDG · iShares Trust 0,38% 4.071 SH 11 Settembre 2026 Giornaliero
BBMC · J.P. Morgan Exchange-Traded Fund Tr… 0,36% 44.021 NS 31 Luglio 2026 N-PORT
MIDU · Direxion Shares ETF Trust 0,36% 1.476 NS 31 Luglio 2026 N-PORT
FSMD · FIDELITY COVINGTON TRUST 0,31% 46.187 NS 31 Luglio 2026 N-PORT
FNX · First Trust Exchange-Traded AlphaDE… 0,30% 24.447 NS 31 Luglio 2026 N-PORT
JPME · J.P. Morgan Exchange-Traded Fund Tr… 0,29% 8.053 NS 31 Luglio 2026 N-PORT
COWZ · Pacer Funds Trust 0,25% 283.150 NS 31 Luglio 2026 N-PORT
IYH · iShares Trust 0,25% 57.843 SH 11 Settembre 2026 Giornaliero
VHT · VANGUARD WORLD FUND 0,24% 286.599 SH 19 Agosto 2026 Giornaliero
FHLC · FIDELITY COVINGTON TRUST 0,23% 45.259 NS 31 Luglio 2026 N-PORT
SMMD · iShares Trust 0,21% 52.744 SH 11 Settembre 2026 Giornaliero
EUSA · iShares, Inc. 0,20% 25.089 SH 11 Settembre 2026 Giornaliero
VB · VANGUARD INDEX FUNDS 0,20% 2.306.077 SH 19 Agosto 2026 Giornaliero
PWS · Pacer Funds Trust 0,20% 287 NS 31 Luglio 2026 N-PORT
SIZE · iShares Trust 0,20% 5.417 SH 11 Settembre 2026 Giornaliero
VXF · VANGUARD INDEX FUNDS 0,19% 1.153.763 SH 19 Agosto 2026 Giornaliero
FAD · First Trust Exchange-Traded AlphaDE… 0,19% 6.541 NS 31 Luglio 2026 N-PORT
ACWV · iShares, Inc. 0,18% 37.854 SH 11 Settembre 2026 Giornaliero
RWK · Invesco Exchange-Traded Fund Trust … 0,13% 11.381 SH 02 Ottobre 2026 Giornaliero
IWR · iShares Trust 0,11% 405.396 SH 11 Settembre 2026 Giornaliero
FHEQ · Fidelity Greenwood Street Trust 0,11% 6.157 NS 31 Luglio 2026 N-PORT
ESUM · Strategy Shares 0,10% 1.133 NS 31 Luglio 2026 N-PORT
HEQQ · J.P. Morgan Exchange-Traded Fund Tr… 0,10% 177 NS 31 Luglio 2026 N-PORT
LRND · New York Life Investments ETF Trust 0,10% 2.270 NS 31 Luglio 2026 N-PORT
HELO · J.P. Morgan Exchange-Traded Fund Tr… 0,09% 23.838 NS 31 Luglio 2026 N-PORT
EQAL · Invesco Exchange-Traded Fund Trust … 0,09% 4.828 SH 02 Ottobre 2026 Giornaliero
DFUV · Dimensional ETF Trust 0,08% 70.759 NS 31 Luglio 2026 N-PORT
OMFL · Invesco Exchange-Traded Self-Indexe… 0,07% 23.598 SH 02 Ottobre 2026 Giornaliero
DYNF · BlackRock ETF Trust 0,07% 177.312 SH 11 Settembre 2026 Giornaliero
USXF · iShares Trust 0,06% 5.665 SH 11 Settembre 2026 Giornaliero
ESMV · iShares Trust 0,05% 26 SH 11 Settembre 2026 Giornaliero
GARP · iShares Trust 0,05% 9.869 SH 11 Settembre 2026 Giornaliero
DFAC · Dimensional ETF Trust 0,05% 141.631 NS 31 Luglio 2026 N-PORT
DXUV · Dimensional ETF Trust 0,05% 1.484 NS 31 Luglio 2026 N-PORT
DCOR · Dimensional ETF Trust 0,04% 8.569 NS 31 Luglio 2026 N-PORT
IUSG · iShares Trust 0,04% 89.338 SH 11 Settembre 2026 Giornaliero
IWF · iShares Trust 0,04% 320.069 SH 11 Settembre 2026 Giornaliero
VONG · VANGUARD SCOTTSDALE FUNDS 0,04% 134.662 SH 19 Agosto 2026 Giornaliero
ESGV · VANGUARD WORLD FUND 0,03% 22.375 SH 19 Agosto 2026 Giornaliero
TILT · FlexShares Trust 0,03% 3.888 NS 31 Luglio 2026 N-PORT
DFAU · Dimensional ETF Trust 0,03% 20.775 NS 31 Luglio 2026 N-PORT
RECS · Columbia ETF Trust I 0,02% 8.549 NS 31 Luglio 2026 N-PORT
DFUS · Dimensional ETF Trust 0,02% 28.885 NS 31 Luglio 2026 N-PORT
IYY · iShares Trust 0,02% 4.355 SH 11 Settembre 2026 Giornaliero
IWB · iShares Trust 0,02% 68.459 SH 11 Settembre 2026 Giornaliero
ITOT · iShares Trust 0,02% 131.068 SH 11 Settembre 2026 Giornaliero
IWS · iShares Trust 0,02% 20.508 SH 11 Settembre 2026 Giornaliero
IWV · iShares Trust 0,02% 27.012 SH 11 Settembre 2026 Giornaliero
PBUS · Invesco Exchange-Traded Fund Trust … 0,02% 16.531 SH 02 Ottobre 2026 Giornaliero
VTI · VANGUARD INDEX FUNDS 0,02% 3.193.839 SH 19 Agosto 2026 Giornaliero
VONE · VANGUARD SCOTTSDALE FUNDS 0,02% 16.227 SH 19 Agosto 2026 Giornaliero
VTHR · VANGUARD SCOTTSDALE FUNDS 0,02% 8.342 SH 19 Agosto 2026 Giornaliero
PRF · Invesco Exchange-Traded Fund Trust 0,02% 11.591 SH 02 Ottobre 2026 Giornaliero
TOK · iShares Trust 0,02% 249 SH 11 Settembre 2026 Giornaliero
URTH · iShares, Inc. 0,02% 8.440 SH 11 Settembre 2026 Giornaliero
ACWI · iShares Trust 0,01% 30.548 SH 11 Settembre 2026 Giornaliero
DFLV · Dimensional ETF Trust 0,01% 4.926 NS 31 Luglio 2026 N-PORT
DFVX · Dimensional ETF Trust 0,01% 323 NS 31 Luglio 2026 N-PORT
VT · VANGUARD INTERNATIONAL EQUITY INDEX… 0,01% 85.082 SH 19 Agosto 2026 Giornaliero
VONV · VANGUARD SCOTTSDALE FUNDS 0,01% 8.319 SH 19 Agosto 2026 Giornaliero
FYEE · Fidelity Greenwood Street Trust 0,01% 110 NS 31 Luglio 2026 N-PORT
REVS · Columbia ETF Trust I 0,01% 124 NS 31 Luglio 2026 N-PORT
IWD · iShares Trust 0,01% 30.627 SH 11 Settembre 2026 Giornaliero
IJH · iShares Trust · 3.528.125 SH 11 Settembre 2026 Giornaliero
IJK · iShares Trust · 582.451 SH 11 Settembre 2026 Giornaliero
XJH · iShares Trust · 13.736 SH 08 Settembre 2026 Giornaliero
ISCB · iShares Trust · 4.526 SH 11 Settembre 2026 Giornaliero

NBIX Consenso degli analisti Opinioni degli analisti, sia rialziste che ribassiste, target price a 12 mesi, potenziale di rialzo

21
rating · 36 analisti COMPRA
Target mediano $214.00 +48,4%
14 38,9% Acquisto forte
17 47,2% Compra
5 13,9% Mantieni
0 0,0% Vendi
0 0,0% Vendita forte

Target Price a 12 Mesi

29 analisti · 2026-10-03

Target medio $207.81 +44,1%

← Sotto tutti i target Prezzo attuale $144.21
Basso$164.00 Media$207.81 Alto$253.00

Confronto Peer (GICS sub-settore industriale) Metriche chiave rispetto ai pari del settore

22

Base FY, prezzi alla chiusura dell'ultimo anno fiscale di ciascuna società.

Ticker Capitalizzazione di Mercato P/E Rev YoY Margine Netto ROE Margine lordo
NBIX $14.20B 30.4 21.4% 16.7% 16.1% ·
ALNY $52.64B 170.7 65.2% 8.5% 60.4% ·
UTHR $21.27B 17.5 10.6% 41.9% 18.7% 87.9%
INCY $19.60B 15.4 21.2% 25.0% 27.6% ·
INSM $37.29B -27.1 66.7% -210.5% -128.4% ·
EXEL $11.44B 15.7 7.0% 33.7% 37.3% ·
SMMT $13.56B -12.1 · · -235.1% ·
TWST $1.71B -21.6 20.3% -20.6% -17.0% ·
BBIO $14.90B -20.2 126.3% -146.0% 41.2% ·
HALO $7.93B 26.3 37.5% 22.7% 166.1% ·
MDGL $13.30B -45.3 432.1% -30.1% -44.4% ·

Ultime notizie Notizie recenti che menzionano questa società

23
Opzioni di Dicembre 2027 Ora Disponibili per Neurocrine Biosciences (NBIX) Nasdaq · 5 mesi, 4 settimane fa Borsa Oggi, 6 Aprile: Soleno Therapeutics in Rialzo Dopo Accordo di Acquisto Totale in Contanti da 2,9 Miliardi di Dollari Nasdaq · 5 mesi, 4 settimane fa Neurocrine per acquisire Soleno per un accordo in contanti da 2,9 miliardi di dollari; il titolo di Soleno sale in pre-mercato Nasdaq · 5 mesi, 4 settimane fa

Segnali di trading Segnali recenti di acquisto/vendita con prezzo di entrata e rapporto rischio/rendimento

25
BLUECHIP_DIP Stop out Set 8
rischio 1 premio 1,67
ingresso $156.04 R:R 1,67
BLUECHIP_DIP Stop out Ago 6
rischio 1 premio 2,78
ingresso $161.50 R:R 2,78
BLUECHIP_DIP Scaduto Apr 28
rischio 1 premio 5,00
ingresso $129.88 R:R 5,00
BLUECHIP_DIP Stop out Apr 20
rischio 1 premio 4,80
ingresso $132.67 R:R 4,80
BLUECHIP_DIP Stop out Apr 9
rischio 1 premio 5,00
ingresso $132.79 R:R 5,00

Nessun segnale aperto al momento — nessuna scheda è compilata, e questo è onesto.

Le Mie Metriche La tua watchlist personale — righe selezionate da Fondamentali Completi

26

Scegli le metriche che contano per te: fai clic sul + accanto a qualsiasi riga in Fondamentali Completi sopra.

La tua selezione è salvata e ti segue su tutti i ticker.

Fonte: SEC 10-Q depositato Lug 31, 2026